financetom
Business
financetom
/
Business
/
Championx Insider Sold Shares Worth $1,482,053, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Championx Insider Sold Shares Worth $1,482,053, According to a Recent SEC Filing
Nov 9, 2024 12:46 PM

06:01 PM EST, 11/07/2024 (MT Newswires) -- Deric D. Bryant, Chief Operating Officer and President, Chemical Technologies, on November 06, 2024, sold 49,303 shares in Championx ( CHX ) for $1,482,053. Following the Form 4 filing with the SEC, Bryant has control over a total of 337,409 shares of the company, with 337,409 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1723089/000172308924000131/xslF345X05/wk-form4_1731020355.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amazon Web Services Signs $38 Billion Cloud Deal With OpenAI
Amazon Web Services Signs $38 Billion Cloud Deal With OpenAI
Nov 3, 2025
12:32 PM EST, 11/03/2025 (MT Newswires) -- Amazon.com ( AMZN ) secured a $38 billion deal with OpenAI that allows the Microsoft ( MSFT )-backed (MSFT) artificial intelligence research lab to run its workloads on Amazon's ( AMZN ) cloud computing division. As part of the deal, the ChatGPT parent gets access to Amazon Web Services' infrastructure comprising hundreds of...
Revolution Medicines is Best-Positioned to Execute Targeting RAS-Mutated Cancers, RBC Says
Revolution Medicines is Best-Positioned to Execute Targeting RAS-Mutated Cancers, RBC Says
Nov 3, 2025
12:32 PM EST, 11/03/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) is positioned to execute targeting rat sarcoma-mutated tumor cancers, given its impressive efficacy data and focused pipeline, RBC Capital Markets said in a Monday research report. Channel checks indicate daraxonrasib's benefits in treating solid tumors with specific RAS mutations could be reproduced in phase 3 trials with a...
Costco's Outperformance Case Strengthens Amid Mixed Consumer Spending, Oppenheimer Says
Costco's Outperformance Case Strengthens Amid Mixed Consumer Spending, Oppenheimer Says
Nov 3, 2025
12:31 PM EST, 11/03/2025 (MT Newswires) -- Costco Wholesale's ( COST ) case for outperformance is now even stronger in a mixed consumer spending backdrop, Oppenheimer said in a Monday note, as it reinstated the stock to its Top Pick list. The brokerage said Costco shares have underperformed year-to-date, down about 1% compared with a 16% gain in the S&P...
Kilroy Realty Set to Benefit From San Francisco Office Rebound After Clearing Hurdles, RBC Says
Kilroy Realty Set to Benefit From San Francisco Office Rebound After Clearing Hurdles, RBC Says
Nov 3, 2025
12:30 PM EST, 11/03/2025 (MT Newswires) -- Kilroy Realty ( KRC ) has cleared its near-term hurdles and should benefit from the ongoing recovery in San Francisco's office market, RBC Capital Markets said in a report Monday. The firm said Kilroy is benefiting from good leasing activity at its KOP2 development and gradual advancement of its Flower Mart re-entitlement process,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved